Japan approves Leqembi Pen subcutaneous dosing for early Alzheimer’s
BioArctic said partner Eisai gained Japanese approval for Leqembi Pen, a once-weekly 500 mg subcutaneous autoinjector for early Alzheimer’s, complementing the IV form.
Story updates
06:19:56 AM UTC
SquawkNews
STOCKHOLM, Sept. 16, 2026 // -- BioArctic AB (publ)'s (NASDAQ STOCKHOLM: BIOA B) partner Eisai announced today that the subcutaneous autoinjector formulation of Leqembi (known as Leqembi Pen in Japan) has been approved as a new route of administration for the treatment of early Alzheimer'…
06:20:51 AM UTC
SquawkNews
BioArctic said partner Eisai gained Japanese approval for Leqembi Pen, a once—weekly 500 mg subcutaneous autoinjector for early Alzheimer’s, complementing the IV form.Material DetailsContext by AI AnalystThis is a mid-cycle expansion of Leqembi’s label, adding a more convenient route likely to supp…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.